Mecbotamab vedotin
As of the edition of 20 October 2026, Mecbotamab vedotin is an antibody drug conjugate: of no established status; acts on AXL.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Status not established
- Kind
- Antibody drug conjugate
- Registered trials
- 2, 0 stopped early
- Disease areas
- Cancer; Hormones; Lungs and airways; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| AXL | Tyrosine-protein kinase receptor UFO | P30530 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 1 | 1 | 0 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| BioAtla | Lead sponsor of trials | 2021 to now |